Regentis Biomaterials Ltd.
RGNT institutional ownership changes in Q2 2026: 3 institutions opened or added positions, 0 trimmed or exited. RGNT (Regentis Biomaterials Ltd.) is held by 3 institutional investors as of Q2 2026. Top institutional shareholders: Jane Street Group, LLC ($152,966), Renaissance Technologies LLC ($47,118), UBS Group AG ($1,532). Institutions were buying, on balance.
Who's Trading
Latest move
Source dates: Price Nov 5, 2026 · Insiders none · Activists Feb 17, 2026 · Congress none
Top Holders
| Action | ||||||
|---|---|---|---|---|---|---|
New | 43,333 | $152,966 | 0.0% | -61.19% | 34 | |
New | 13,348 | $47,118 | 0.0% | -61.19% | 28 | |
Increased | 434(+29.9%) | $1,532 | 0.0% | -56.71% | 10 |
Continue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Incorporated
LLYEli Lilly and Company
TMOThermo Fisher Scientific Inc
JNJJohnson & Johnson
DHRDanaher Corporation
ISRGIntuitive Surgical, Inc.
MRKMerck & Company, Inc.
ABBVAbbVie Inc.
BSXBoston Scientific Corporation
ABTAbbott LaboratoriesQuestions investors ask about RGNT
Who owns RGNT?
3 institutional investors held RGNT on June 30, 2026, led by Jane Street Group, LLC ($152,966), Renaissance Technologies LLC ($47,118) and UBS Group AG ($1,532).
How many hedge funds hold RGNT?
3 institutional investors reported RGNT in their 13F filings for the quarter ended June 30, 2026, $201,616 in all.
Are institutions buying or selling RGNT?
Buying, on balance. In Q2 2026, 3 institutions opened or added to positions in RGNT and 0 institutions trimmed or exited.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer